Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.63 |
| ▸ | NPC1 | O15118 | 10/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | PKM | P14618 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.43 |
| ▸ | RELA | Q04206 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21301203 | 1.00 | RAB9A (0.63) | RAB9AALDH1A1NPC1KDM4EL3MBTL1 | |
| SCHEMBL15069020 | 0.91 | ALDH1A1 (0.61) | RAB9AALDH1A1NPC1KDM4EL3MBTL1 | |
| SCHEMBL15068729 | 0.91 | ALDH1A1 (0.61) | RAB9AALDH1A1NPC1KDM4EL3MBTL1 | |
| SCHEMBL15068555 | 0.90 | NPC1 (0.49) | RAB9AALDH1A1NPC1KDM4EL3MBTL1 | |
| SCHEMBL15068875 | 0.90 | NPC1 (0.49) | RAB9AALDH1A1NPC1KDM4EL3MBTL1 | |
| SCHEMBL15068734 | 0.89 | CASP1 (0.51) | RAB9AALDH1A1NPC1KDM4EL3MBTL1 | |
| SCHEMBL15069159 | 0.88 | NPC1 (0.46) | RAB9AALDH1A1NPC1KDM4EL3MBTL1 | |
| SCHEMBL15068485 | 0.88 | NPC1 (0.47) | RAB9AALDH1A1NPC1KDM4EL3MBTL1 | |
| SCHEMBL15068907 | 0.86 | NPC1 (0.45) | RAB9AALDH1A1NPC1KDM4EL3MBTL1 | |
| SCHEMBL15068723 | 0.86 | NPC1 (0.45) | RAB9AALDH1A1NPC1KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE47689-E1 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2019-11-05 | — | — | US | claimed |
| US-9617268-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2017-04-11 | — | — | US | claimed |
| WO-2015095449-A1 | METHODS FOR MODULATING THE AMOUNT RNA TRANSCRIPTS | PTC THERAPEUTICS, INC. (US) | 2015-06-25 | — | — | WO | claimed |
| US-20150119380-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-30 | — | — | US | claimed |
| EP-2797592-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC Therapeutics, Inc. (US) | 2014-11-05 | — | — | EP | claimed |
| WO-2013101974-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | WO | claimed |
| US-RE47689-E1 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| EP-2797592-B1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC (US) | 2019-08-28 | — | — | EP | disclosed |
| EP-2797592-B1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC (US) | 2019-08-28 | — | — | EP | disclosed |
| US-9617268-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617268-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| WO-2015095449-A1 | METHODS FOR MODULATING THE AMOUNT RNA TRANSCRIPTS | PTC THERAPEUTICS, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015095449-A1 | METHODS FOR MODULATING THE AMOUNT RNA TRANSCRIPTS | PTC THERAPEUTICS, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20150119380-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-30 | — | — | US | disclosed |
| US-20150119380-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-30 | — | — | US | disclosed |
| WO-2013101974-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119380-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, RBM17, RBM22 | RAB9A 3292/4885ALDH1A1 1006/4885NPC1 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.